Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes

References

• GallePR, FornerA, LlovetJMet al.EASL clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol.69(1), 182–236 (2018).
   PubMed Web of Science ®Google Scholar
• HeimbachJK, KulikLM, FinnRSet al.AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology67(1), 358–380 (2018).
   PubMed Web of Science ®Google Scholar
• FornerA, ReigM, BruixJ. Hepatocellular carcinoma. Lancet391(10127), 1301–1314 (2018).
   PubMed Web of Science ®Google Scholar
• SanMiguel C, MuffakK, TrigueroJet al.Role of transarterial chemoembolization to downstage hepatocellular carcinoma within the Milan criteria. Transplant. Proc.47(9), 2631–2633 (2015).
   PubMed Web of Science ®Google Scholar
• PomfretEA, WashburnK, WaldCet al.Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl.16(3), 262–278 (2010).
   PubMed Web of Science ®Google Scholar
• GaoS, YangZ, ZhengZet al.Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology60(124), 813–820 (2013).
   PubMedGoogle Scholar
• LammerJ, MalagariK, VoglTet al.Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION v study. Cardiovasc. Intervent. Radiol.33(1), 41–52 (2010).
   PubMed Web of Science ®Google Scholar
• GolfieriR, GiampalmaE, RenzulliMet al.Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br. J. Cancer111(2), 255–264 (2014).
   PubMed Web of Science ®Google Scholar
• AlibertiC, CarandinaR, SartiDet al.Hepatic arterial infusion of polyethylene glycol drug-eluting beads for primary and metastatic liver cancer therapy. Anticancer Res.36(7), 3515–3521 (2016).
   PubMed Web of Science ®Google Scholar
• AlibertiC, CarandinaR, SartiDet al.Chemoembolization adopting polyethylene glycol drug-eluting embolics loaded with doxorubicin for the treatment of hepatocellular carcinoma. AJR Am. J. Roentgenol.209(2), 430–434 (2017).
   PubMed Web of Science ®Google Scholar
• Veloso GomesF, OliveiraJA, CorreiaMTet al.Chemoembolization of hepatocellular carcinoma with drug-eluting polyethylene glycol embolic agents: single-center retrospective analysis in 302 patients. J. Vasc. Interv. Radiol.29(6), 841–849 (2018).
   PubMed Web of Science ®Google Scholar
• AraiH, AbeT, TakayamaHet al.Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma. Hepatol. Res.45(6), 663–666 (2015).
   PubMed Web of Science ®Google Scholar
• MaruyamaM, YoshizakoT, NakamuraT, NakamuraM, YoshidaR, KitagakiH. Initial experience with balloon-occluded trans-catheter arterial chemoembolization (B-TACE) for hepatocellular carcinoma. Cardiovasc. Intervent. Radiol.39(3), 359–366 (2016).
   PubMed Web of Science ®Google Scholar
• HatanakaT, AraiH, KakizakiS. Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. World J. Hepatol.10(7), 485–495 (2018).
   PubMedGoogle Scholar
• IrieT, KuramochiM, KamoshidaT, TakahashiN. Selective balloon-occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules: retrospective comparison with conventional super-selective TACE. Hepatol. Res.46(2), 209–214 (2016).
   PubMed Web of Science ®Google Scholar
• OgawaM, TakayasuK, HirayamaMet al.Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: short-term results. Hepatol. Res.46(3), E60–E69 (2016).
   PubMed Web of Science ®Google Scholar
• LucatelliP, GinnaniCorradini L, DeRubeis Get al.Balloon-occluded transcatheter arterial chemoembolization (b-TACE) for hepatocellular carcinoma performed with polyethylene-glycol epirubicin-loaded drug-eluting embolics: safety and preliminary results. Cardiovasc. Intervent. Radiol.42(6), 853–862 (2019).
   PubMed Web of Science ®Google Scholar
• GoldmanDT, SinghM, PatelRSet al.Balloon-occluded transarterial chemoembolization for the treatment of hepatocellular carcinoma: a single-center US preliminary experience. J. Vasc. Interv. Radiol.30(3), 342–346 (2019).
   PubMed Web of Science ®Google Scholar
• FilippiadisDK, BinkertC, PellerinO, HoffmannRT, KrajinaA, PereiraPL. Cirse quality assurance document and standards for classification of complications: the Cirse classification system. Cardiovasc. Intervent. Radiol.40(8), 1141–1146 (2017).
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE).v.5.0 (2017). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
   Google Scholar
• LencioniR, LlovetJM. Modified recist (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis.30(1), 52–60 (2010).
   PubMed Web of Science ®Google Scholar
• MazzaferroV, RegaliaE, DociRet al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med.334(11), 693–699 (1996).
   PubMed Web of Science ®Google Scholar
• YaoFY, FerrellL, BassNMet al.Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology33(6), 1394–1403 (2001).
   PubMed Web of Science ®Google Scholar
• MinamiY, MinamiT, ChishinaHet al.Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma: a single-center experience. Oncology89(Suppl. 2), 27–32 (2015).
   PubMedGoogle Scholar
• MalagariK, PomoniM, SpyridopoulosTNet al.Safety profile of sequential transcatheter chemoembolization with DC bead™: results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc. Intervent. Radiol.34(4), 774–785 (2011).
   PubMed Web of Science ®Google Scholar
• AramburuJ, AntónR, RivasAet al.Numerical zero-dimensional hepatic artery hemodynamics model for balloon-occluded transarterial chemoembolization. Int. J. Numer. Method Biomed. Eng.34(7), e2983 (2018).
   PubMed Web of Science ®Google Scholar
• GuiuB, DeschampsF, AhoSet al.Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J. Hepatol.56(3), 609–617 (2012).
   PubMed Web of Science ®Google Scholar